News Briefs: CMS Gets Agreements With Sickle Cell Gene Therapy Companies
-
Dec 12, 2024
CMS has come to an agreement with the manufacturers of two gene therapies for sickle cell disease to participate in the Cell and Gene Therapy Access Model, it said on Dec. 4. The voluntary model will first test outcomes-based agreements for bluebird bio, Inc’s Lyfgenia (lovotibeglogene autotemcel) and Vertex Pharmaceuticals Inc. and CRISPR Therapeutics’ Casgevy (exagamglogene autotemcel) for people with Medicaid in an attempt to improve patient outcomes, expand access to cell and gene therapies and lower health care costs. The FDA approved both agents on Dec. 8, 2023. Lyfgenia’s wholesale acquisition cost is $3.1 million for a one-time treatment, while Casgevy’s WAC is $2.2 million. The state application portal is live, and states and U.S. territories that participate in the Medicaid Drug Rebate Program can sign up through Feb. 28, 2025. They can choose to start participating at any time between January 2025 and January 2026. States may also apply for optional model funding by Feb. 28. Read more
© 2024 MMIT
The Latest
Meet Our Reporters
Meet Our Reporters
GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND
Sign up for publications to get unmatched business intelligence delivered to your inbox.